In silico analysis of small molecule compounds based on pharmacophore- and backbone-leaping peroxiredoxin 1 (PRDX1) inhibitors

References

• Bai, Y., Liang, C., Zhou, J., Liu, Y., Wang, F., Gao, J., Wu, J., & Hu, D. (2023). Development of novel celastrol-ligustrazine hybrids as potent peroxiredoxin 1 inhibitors against lung cancer. European Journal of Medicinal Chemistry, 259, 115656. https://doi.org/10.1016/j.ejmech.2023.115656
   PubMed Web of Science ®Google Scholar
• Chu, G., Li, J., Zhao, Y., Liu, N., Zhu, X., Liu, Q., Wei, D., & Gao, C. (2016). Identification and verification of PRDX1 as an inflammation marker for colorectal cancer progression. American Journal of Translational Research, 8(2), 842–859.
   PubMed Web of Science ®Google Scholar
• Cong, N., Huang, W., Yuan, J. P., Li, G. Z., Zhai, G. S., & Li, B. S. (2018). Peroxiredoxin1 promotes cell proliferation, migration and invasion of colorectal cancer via p38MAPK signaling. European Review for Medical and Pharmacological Sciences, 22(7), 1922–1928. https://doi.org/10.26355/eurrev_201804_14715
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Ding, C., Fan, X., & Wu, G. (2017). Peroxiredoxin 1 - an antioxidant enzyme in cancer. Journal of Cellular and Molecular Medicine, 21(1), 193–202. https://doi.org/10.1111/jcmm.12955
   PubMed Web of Science ®Google Scholar
• Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., & Friesner, R. A. (2006). PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design, 20(10-11), 647–671. https://doi.org/10.1007/s10822-006-9087-6
   PubMed Web of Science ®Google Scholar
• Hoshino, I., Matsubara, H., Akutsu, Y., Nishimori, T., Yoneyama, Y., Murakami, K., Sakata, H., Matsushita, K., & Ochiai, T. (2007). Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncology Reports, 18(4), 867–871. https://doi.org/10.3892/or.18.4.867
   PubMed Web of Science ®Google Scholar
• Keum, N., & Giovannucci, E. (2019). Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nature Reviews. Gastroenterology & Hepatology, 16(12), 713–732. https://doi.org/10.1038/s41575-019-0189-8
   PubMed Web of Science ®Google Scholar
• Kirchmair, J., Markt, P., Distinto, S., Wolber, G., & Langer, T. (2008). Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection–what can we learn from earlier mistakes? Journal of Computer-Aided Molecular Design, 22(3-4), 213–228. https://doi.org/10.1007/s10822-007-9163-6
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., Open Source Drug Discovery, C., & Lynn, A, Open Source Drug Discovery Consortium. (2014). g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Kumer, A., Chakma, U., & Matin, M. (2022). Bilastine based drugs as SARS-CoV-2 protease inhibitors: molecular docking, dynamics, and ADMET related studies. Orbital - The Electronic Journal of Chemistry, 14, 15–23. https://doi.org/10.17807/orbital.v14i1.1642
   Web of Science ®Google Scholar
• Li, J., Fu, A., & Zhang, L. (2019). An overview of scoring functions used for protein-ligand interactions in molecular docking. Interdisciplinary Sciences, Computational Life Sciences, 11(2), 320–328. https://doi.org/10.1007/s12539-019-00327-w
   PubMed Web of Science ®Google Scholar
• Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J. L., Dror, R. O., & Shaw, D. E. (2010). Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins, 78(8), 1950–1958. https://doi.org/10.1002/prot.22711
   PubMed Web of Science ®Google Scholar
• Luo, P., Liu, D., Zhang, Q., Yang, F., Wong, Y.-K., Xia, F., Zhang, J., Chen, J., Tian, Y., Yang, C., Dai, L., Shen, H.-M., & Wang, J. (2022). Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1. Acta Pharmaceutica Sinica. B, 12(5), 2300–2314. https://doi.org/10.1016/j.apsb.2021.12.007
   PubMed Web of Science ®Google Scholar
• Luo, L., Tan, H., & Liao, Y. (2023). In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking. Journal of Biomolecular Structure & Dynamics, 41(22), 13180–13197. https://doi.org/10.1080/07391102.2023.2184172
   PubMedGoogle Scholar
• Luo, L., Yao, X., Xiang, J., Huang, F., & Luo, H. (2022). Identification of ferroptosis-related genes for overall survival prediction in hepatocellular carcinoma. Scientific Reports, 12(1), 10007. https://doi.org/10.1038/s41598-022-14554-7
   PubMed Web of Science ®Google Scholar
• Luo, L., Zhong, A., Wang, Q., & Zheng, T. (2021). Structure-based pharmacophore modeling, virtual screening, molecular docking, ADMET, and molecular dynamics (MD) simulation of potential inhibitors of PD-L1 from the library of marine natural products. Marine Drugs, 20(1), 29. https://doi.org/10.3390/md20010029
   PubMed Web of Science ®Google Scholar
• Lv, C., Huang, Y., Wang, Q., Wang, C., Hu, H., Zhang, H., Lu, D., Jiang, H., Shen, R., Zhang, W., & Liu, S. (2023). Ainsliadimer A induces ROS-mediated apoptosis in colorectal cancer cells via directly targeting peroxiredoxin 1 and 2. Cell Chemical Biology, 30(3), 295–307 e295. https://doi.org/10.1016/j.chembiol.2023.02.003
   PubMed Web of Science ®Google Scholar
• Matsuda, T., Yamashita, K., Hasegawa, H., Oshikiri, T., Hosono, M., Higashino, N., Yamamoto, M., Matsuda, Y., Kanaji, S., Nakamura, T., Suzuki, S., Sumi, Y., & Kakeji, Y. (2018). Recent updates in the surgical treatment of colorectal cancer. Annals of Gastroenterological Surgery, 2(2), 129–136. https://doi.org/10.1002/ags3.12061
   PubMed Web of Science ®Google Scholar
• Neumann, C. A., Krause, D. S., Carman, C. V., Das, S., Dubey, D. P., Abraham, J. L., Bronson, R. T., Fujiwara, Y., Orkin, S. H., & Van Etten, R. A. (2003). Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature, 424(6948), 561–565. https://doi.org/10.1038/nature01819
   PubMed Web of Science ®Google Scholar
• Sanaullah, A. F. M., Devi, P., Hossain, T., Sultan, S. B., Badhon, M. M. U., Hossain, M. E., Uddin, J., Patwary, M. A. M., Kazi, M., & Matin, M. M. (2023). Rhamnopyranoside-based fatty acid esters as antimicrobials: synthesis, spectral characterization, PASS, antimicrobial, and molecular docking studies. Molecules (Basel, Switzerland), 28(3), 986. https://doi.org/10.3390/molecules28030986
   PubMed Web of Science ®Google Scholar
• Triballeau, N., Acher, F., Brabet, I., Pin, J. P., & Bertrand, H. O. (2005). Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of Medicinal Chemistry, 48(7), 2534–2547. https://doi.org/10.1021/jm049092j
   PubMed Web of Science ®Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Veselovsky, A. V., & Ivanov, A. S. (2003). Strategy of computer-aided drug design. Current Drug Targets. Infectious Disorders, 3(1), 33–40. https://doi.org/10.2174/1568005033342145
   PubMedGoogle Scholar
• Xiao, H., Yang, T., Yan, L., Feng, J., Huang, B., & Jiang, Y. (2020). PRDX1 is a tumor suppressor for nasopharyngeal carcinoma by inhibiting PI3K/AKT/TRAF1 signaling. OncoTargets and Therapy, 13, 9123–9133. https://doi.org/10.2147/OTT.S252286
   PubMed Web of Science ®Google Scholar
• Xu, S., Ma, Y., Tong, Q., Yang, J., Liu, J., Wang, Y., Li, G., Zeng, J., Fang, S., Li, F., Xie, X., & Zhang, J. (2021). Cullin-5 neddylation-mediated NOXA degradation is enhanced by PRDX1 oligomers in colorectal cancer. Cell Death & Disease, 12(3), 265. https://doi.org/10.1038/s41419-021-03557-3
   PubMed Web of Science ®Google Scholar
• Xu, H., Zhao, H., Ding, C., Jiang, D., Zhao, Z., Li, Y., Ding, X., Gao, J., Zhou, H., Luo, C., Chen, G., Zhang, A., Xu, Y., & Zhang, H. (2023). Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. Signal Transduction and Targeted Therapy, 8(1), 51. https://doi.org/10.1038/s41392-022-01231-4
   PubMed Web of Science ®Google Scholar
• Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. A.-O. (2019). Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chemical reviews, 119(18). https://doi.org/10.1021/acs.chemrev.8b00728
   Google Scholar
• Zhou, X., Liang, Z., Li, K., Fang, W., Tian, Y., Luo, X., Chen, Y., Zhan, Z., Zhang, T., Liao, S., Liu, S., Liu, Y., Fenical, W., & Tang, L. (2019). Exploring the natural piericidins as anti-renal cell carcinoma agents targeting peroxiredoxin 1. Journal of Medicinal Chemistry, 62(15), 7058–7069. https://doi.org/10.1021/acs.jmedchem.9b00598
   PubMed Web of Science ®Google Scholar